Latest Breaking News On - ஜெனோவா முயற்சிகள் - Page 1 : comparemela.com

Theranos founder wooed believers in parallel universe

Theranos founder wooed believers in parallel universe
bangkokpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bangkokpost.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesJenny rookeHenry kissingerSteve jobsJim mattisJohn carreyrouElizabeth holmesKara swisherAdam rosendorffRupert murdochNew york timesSilicon valleySan joseMiss holmesGenoa ventures

Filipino biotech firm InterVenn raises P10B for immuno-oncology test

Filipino biotech firm InterVenn raises P10B for immuno-oncology test
bworldonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bworldonline.com Daily Mail and Mail on Sunday newspapers.

Pasig cityCity of pasigUnited statesDavis schoolSan franciscoIntervenn biosciencesAldo carrascosoJeninap ibaUniversity of californiaBabson collegeSoftbank groupAteneo de manila universityHeritage provider networkVenn biosciencesIrving investorsVenn chief executive officer

Follow the Money: RNA Therapeutics, AI-Driven Therapy Design

Follow the Money: RNA Therapeutics, AI-Driven Therapy Design
bio-itworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bio-itworld.com Daily Mail and Mail on Sunday newspapers.

Thurgood marshall collegeUnited statesNew south walesNew zealand generalNew zealandAl iskandariyahHenry wardMegan callahanGina rinehartDavid kelleherIntervenn biosciencesRaphael gottardoEd tourtellotteKlay thompsonAsia pacificJonathan bush

InterVenn Biosciences Raises $201M in Series C Funding

InterVenn Biosciences, a South San Francisco, Calif.-based company that utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine, completed a $201m Series C financing. The round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. The company intends to use the funds to accelerate development and commercialization of Dawn™, a liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on its AI-driven glycoproteomics platform to accelerate development and commercialization of new clinical solutions, and broaden insights into new biomarkers and therapies.

Intervenn biosciencesAldo carrascosoSoftbank groupHeritage provider networkSouth san franciscoIrving investorsHighside capital managementAmplify partnersAnzu partnersGenoa venturesChief executive officerசாப்ட் பேங்க் குழுபாரம்பரியம் வழங்குநர் வலைப்பின்னல்தெற்கு சான் பிரான்சிஸ்கோஇவிஂக் முதலீட்டாளர்கள்ஹைசைடு மூலதனம் மேலாண்மை

Stemson Therapeutics Raises $15M in Series A Funding

Stemson Therapeutics Raises $15M in Series A Funding Stemson Therapeutics, a San Diego, CA-based pre-clinical stage cell therapy company, closed a $15m Series A financing. The round was led by DCVC Bio with participation from Genoa Ventures, AbbVie Ventures and other investors. In addition, Kiersten Stead, Ph.D., Co-Managing Partner at DCVC Bio and Jenny Rooke, Ph.D., Managing Director at Genoa Ventures will join Stemson’s Executive Chairman Matt Posard and Chief Executive Officer and co-founder Geoff Hamilton on the board of directors. The company intends to use the funds to advance development of its proprietary therapeutic solution to cure hair loss.

San diegoUnited statesJenny rookeGeoff hamiltonMatt posardStemson therapeuticsGenoa venturesAbbvie venturesKiersten steadCo managing partnerManaging directorExecutive chairmanChief executive officerInduced pluripotent stem cellசான் டியாகோஒன்றுபட்டது மாநிலங்களில்